The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'


Roche?s Genentech taps A-lister Morgan Freeman for cancer PSA.....           FiercePharmaAsia: Takeda-Lightstone?s neuroscience JV, China?s accelerating cancer research, Sun?s Halol plant, and more.....           Mylan scores review of Allergan's Restasis IP, but analysts aren't worried about the med's fate.....           Horizon Pharma stops development of Actimmune for Friedreich's ataxia.....           Perrigo plans to restructure Branded Consumer Healthcare's Belgium business.....           Endo returns rights for BELBUCA to BioDelivery Sciences International.....           Cardiome Pharma launches Xydalba (dalbavancin) in UK.....           Gilead Sciences submits NDA to FDA for once-daily triple combo HCV pill.....           FDA grants Biohaven?s orphan drug designation request for BHV-0223.....           'Bribes,' 'kickbacks,' and 'fantastic' nights get ex-Insys CEO, execs indicted for conspiracy.....           Endo to cut loose 375 sales reps, staffers as it sidelines pain meds.....           Ex-VP sues Bayer, saying she defended a pregnant colleague and got whacked for it.....           Top of 2017's pharma heap? Pfizer, Novartis, Roche?and 7 drugs headed for biosim attack.....           Up to 80 Perrigo staffers face the ax in Belgium as struggling Omega unit gets a revamp.....           Teva, already facing $500M-plus penalties for bribery, probes claims it paid off docs in Romania.....           Feds arrest former Insys CEO, execs in 'nationwide conspiracy' to boost Subsys scripts.....           Pharma?s bad jobs week gets worse: AstraZeneca to cut 700 U.S. positions.....           European Commission approves new indication for Novartis? Lucentis eye drug.....           Cascadian Therapeutics amends HER2CLIMB phase 2 trial of tucatinib.....           Sermonix signs licensing deal to further explore lasofoxifene for breast cancer treatment.....           Aclaris starts phase 1 trial for ATI-50001 to treat alopecia totalis and alopecia universalis.....           Research shows flickering lights could be used in Alzheimer's treatment.....           Here's an FDA overhaul: Trump considers Thiel VC partner as commissioner, Bloomberg reports.....           Eylea-maker Bayer rolls out diabetic eye disease awareness and advocacy campaign.....           Mylan eyes up to 3,500 layoffs in post-M&A cost-cutting drive.....           Amgen teams with NPR-famed StoryCorps to collect and share myeloma stories.....           Celgene cuts work on 'encouraging' Abraxane regimen, turns to IO combos instead.....           Trump takes aim at pharma, promising 'I'm going to bring down drug prices'.....           Here's an FDA overhaul: Trump considers Thiel VC partner as agency commish, Bloomberg reports.....           AstraZeneca's Tagrisso reduces lung cancer progression by 70% in phase III study.....           UK's CMA fines Pfizer and Flynn Pharma for epilepsy drug price hike.....           FDA grants fast track designation for Theravance's Velusetrag for idiopathic and diabetic gastroparesis.....           Genentech gets FDA approval for Avastin plus chemotherapy for specific type of advanced ovarian cancer.....           Novartis' Zykadia beats chemotherapy in phase III lung cancer study.....           Bayer rolls out diabetic eye care campaign to grow Eylea amid march to Monsanto merger.....           Can Celgene's Revlimid compete in CLL? With AbbVie's Imbruvica around, maybe not.....           AstraZeneca's Tagrisso, aiming for $3B in sales, trounces chemo in new phase 3 trial.....           Embattled Teva's surprise generics CEO switch shocks analysts, scares investors.....           Pricing, access to drive debate as new meds push 2021 drug spending to $1.5T.....           Adapt hires McCann Health Canada for naloxone nasal spray launch.....           Pfizer's Bosulif found superior to Gleevec in phase 3 study in type of leukemia.....           Novo Nordisk seeks US and EU approval for new type 2 diabetes treatment.....           Aegerion Pharmaceuticals signs licensing deal with Amryt Pharma for Lojuxta.....           Matinas starts dosing in phase 1 study of orally administered aminoglycoside antibiotic MAT2501.....           Purdue Pharma, AnaBios partner to advance research for non-opioid, non-NSAID compounds.....           Lilly helps docs connect patients to resources with 'Yelp for cancer patients'.....           AstraZeneca to shuffle off U.K. finance jobs as part of $1.1B cost-cutting scheme.....           Lilly nets best-case Jardiance nod from FDA, clearing reps to talk up CV risk reduction.....           More Glaxo 'musical execs' as Waterhouse tapped to replace ViiV Healthcare CEO.....           Who wants to be a billionaire? Not Actelion?s founder and CEO, if it means selling out.....           FDA approves cardiovascular indication for Jardiance.....           GSK seeks EU approval for inhaled triple combo COPD therapy.....           Pfizer?s Glasdegib improves OS in AML and MDS patients in phase 2 trial.....           Shire's VONVENDI meets primary endpoint in controlling bleeding in VWD adults in phase 3 study.....           Amgen and Allergan submit bevacizumab biosimilar application to EMA.....           Pharma companies are upping their U.K. social media marketing game with country-specific accounts.....           Are DTC ads tipping the balance in psoriasis battle between Lilly?s Taltz and Novartis? Cosentyx?.....           Merck's Keytruda wins NICE backing in lung cancer with new data, discount.....           What's wrong with the drug pricing climate? Ask a different pharma CEO, get a different answer.....           Mylan takes 'full responsibility' for EpiPen price hikes, but Sen. Grassley still wants answers.....           Valeant looks to revive Xifaxan with primary care sales effort. Will it work?.....           Pfizer, IBM partner to advance immuno-oncology research.....           Bicycle, AstraZeneca enter into potential $1bn multitarget collaboration.....           Daiichi Sankyo?s breast cancer drug candidate gets FDA fast track designation.....           ACADIA begins phase 2 trial of Nuplazid in major depressive disorder.....           Agilis' AADC gene therapy candidate gets OMP designation in Europe.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
 
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
 
 
PharmSci 2017 - first announcement

Tuesday 5 - Thursday 7 September 2017 at De Havilland Campus, University of Hertfordshire, Hatfield

The theme of the conference in 2017 is:
Pharmaceutical Science without Borders.

The APS is pleased to announce Professor Abdul Basit as this year's Conference Science Chair.

Professor of Pharmaceutics at the School of Pharmacy, University College London, where he leads a research group investigating drug delivery to the gastrointestinal tract.

"I am delighted to be Chairing the 8th APS International PharmSci Conference 2017 at the University of Hertfordshire, where our focus this year is "Pharmaceutical Science without Borders". Pharmaceutical science transcends a multitude of borders - it is very much an international field, collaborative in nature and underpins medicines development. The healthcare challenges we face today are global, and cannot be addressed in isolation. Our aim in this conference is to connect, empower and inspire those of you across the pharmaceutical sciences sector and beyond; to broaden your research goals and horizons alongside showcasing pragmatic approaches to trouble-shooting/problem-solving in the pharmaceutical sciences. I look forward to welcoming you to what will no doubt be a fascinating and intellectually stimulating event."

You can become part of this conference now.

Reserve the date, suggest a topic, offer a poster presentation, reserve an exhibition space and many other opportunities. Please email info@apsgb.org.

Please also regularly check here for updates.
 

PharmSci 2016 Conference - Chair's review

The Chair of the Academy of Phamaceutical Sciences, Dr Linda Hakes, gives a brief review of the 7th APS International PharmSci Conference, held in Glasgow on 5-7 September 2016.

"2016 has come to an end and although I admit that I am probably biased, I think it was a fantastic three days. The venue, the Technology and Innovation Centre at Strathclyde University, was well equipped to handle the conference and the facilities are modern and efficient.

All of the conference sessions (as far as I could tell) were well attended and the plenary lectures were all excellent, covering topics ranging across the spectrum of pharmaceutical sciences, embracing chemistry, pharmacology, medical devices, formulation, pharmacokinetics and spectroscopy.

A highlight of the social side was the Civic Reception in the City Chambers, a magnificent building on George Square, where we were warmly welcomed by the Bailey Steward on behalf of the Lord Provost of Glasgow.

 

 

 

 

 

As always the Black Tie Dinner was a great success and we were pleased to have Prof. Sandy Florence as guest speaker. Again, the venue was truly impressive – the Barony Hall.

 

 

 

 


To sum up, I believe we enjoyed a conference full of good science, excellent networking opportunities, and highly enjoyable social events. If you weren’t there, why not make a note for next year –
Tuesday 5 - Thursday 7 September 2017 at the University of
Hertfordshire .

See you there!"

Latest News
APS Fellowships Announcement 2017
WEDNESDAY, 2 NOVEMBER 2016
Do you know someone who has made a significant contribution to Pharmaceutical Science?. The APS is calling for nominations of candidates to become Fellow or Eminent Fellow of the Academy of Pharmaceutical Sciences.. Nominees for Fellowship must be a member of APS (for at least one year) and have a proven track record in pharmaceutical science, as demonstrated by at least 15 peer-reviewed publications, patents or equivalent. This would include significant contributions to the development of products or medical devises within the pharmaceutical industry. Nominees must also have demonstrated leadership and peer recognition through invited lectures, conference leadership, mentoring of young scientists etc. Candidates may self-nominate and nominations must consist of a one-page summary of achievements accompanies by a CV.. Nominations for Eminent Fellowship may be submitted by any member of APS but self-nominations are not accepted. Nominees for Eminent Fellowship must have international recognition for their advocacy of science and have demonstrated leadership at international level. Nominations should consist of a one-page summary of achievements and an explanation of why Eminent Fellowship is justified, and be accompanied by a CV.. Nominations should be sent to info@apsgb.org by 1 March 2017.
APS 8th International PharmSci Conference 2017
TUESDAY, 1 NOVEMBER 2016
. Tuesday 5 - Thursday 7 September 2017 De Havilland Campus, University of Hertfordshire, Hatfield. The theme of the conference in 2017 is. 'Pharmaceutical Science without Borders'. The APS is pleased to announce Professor Abdul Basit as the Conference Science Chair Professor of Pharmaceutics at the School of Pharmacy, University College London, where he leads a research group investigating drug delivery to the gastrointestinal tract.. “I am delighted to be Chairing the 8th APS International PharmSci Conference 2017 at the University of Hertfordshire, where our focus this year is “Pharmaceutical Science without Borders”. Pharmaceutical science transcends a multitude of borders – it is very much an international field, collaborative in nature and underpins medicines development. The healthcare challenges we face today are global, and cannot be addressed in isolation. Our aim in this conference is to connect, empower and inspire those of you across the pharmaceutical sciences sector and beyond; to broaden your research goals and horizons alongside showcasing pragmatic approaches to trouble-shooting/problem-solving in the pharmaceutical sciences. I look forward to welcoming you to what will no doubt be a fascinating and intellectually stimulating event.”. . You can become part of this conference now,. Reserving the date, suggest a topic, offer a poster presentation, reserve an exhibition space and many other opportunities. Please email info@apsgb.org.. . . . . . .
APS thanks retiring Board members and welcomes Yvonne Perrie and Michael Leane as newly appointed Board members
TUESDAY, 4 OCTOBER 2016
At the AGM on 5 September, held during the PharmSci conference at the Technology and Innovation Centre at Strathclyde University, we formally thanked our two retiring Board members, Richard Storey and Claire Thompson, for all their hard work and support of APS over several years of service. Claire has been an enthusiastic Board member who has been a strong advocate for pharmaceutical science and has been very engaged in outreach to universities, students and young scientists. Richard Storey has served not only as a Board member but has also been our Treasurer for many years, a task which has had many challenges which he has managed in a calm and professional manner. We are very grateful to both of them and hope that they will remain active members and supporters of APS.. . At the AGM we also ratified the selection of Yvonne Perrie (Strathclyde University) and Michael Leane (BMS) as the incoming Board members. We warmly welcome them to the Board and look forward to working with them.
APS Symposium on the Digital Design of Drug Products
MONDAY, 13 JUNE 2016
APS Symposium on the Digital Design of Drug Products 1st July 2016, University of Leeds. The design of new medicinal products is a risky and lengthy process. Current approaches utilise a make and test philosophy to understand processing risk. This requires large amounts of materials and knowledge is often limited by short development timelines and availability of input materials. Hence formulations are often developed that merely accommodate variability in drug substance rather than making it an opportunity and thus a heavily over-engineered formulation and process can be produced. The area of digital design has the opportunity to revolutionise the development and manufacturing of new medicines by utilising both mechanistic and big data approaches to produce holistic models for our processes. This will allow optimal processes and materials to be produced which will permit more rapid development and result in improved robustness of manufacturing processes. This event brings together the concept of materials engineering with state of the art knowledge around modelling of materials and processes. It will provide information around initiatives in the pharmaceutical arena where data sharing is helping to produce better guidelines for processes. An opportunity will also be provided to learn about the recently £24M funded ADDoPT (Advanced Digital Design on Pharmaceutical Therapeutics) project which is aimed to provide new tools to the industry in the area of materials manufacture and processing. The meeting is organised by the Academy of Pharmaceutical Sciences but is kindly facilitated by BACG and CGOM. It is a must attend for scientists and leaders in the pharmaceutical development and manufacturing sector as well as an opportunity for other manufacturing industries to learn about new developments that could be adopted on their processes. For more details please contact C.Y.Ma@Leeds.ac.uk Registration for the APS Symposium is now open. Register here: http://www.crystalgrowth2016.co.uk/aps/. On Thursday evening, before the APS Symposium, Tommy Dolan will be giving an evening lecture on “The Future of Medicines Manufacture: Towards Digital Design”. The Conference dinner will also be taking place on Thursday evening. Expressions of interest for the evening lecture series will be opened closer to the event but the conference dinner and accommodation at the University of Leeds can be booked in addition to your APS registration. Friday 1st July – APS Symposium 09:30 10:00 Registration & Refreshments 10:00 10:05 Welcome – Richard Storey, AstraZeneca/APS Treasurer 10:05 10:45 Keynote #1 – Calvin Sun, University of Minnesota The Materials Science Tetrahedron – The Academic Vision Invited modelling presentations 10:45 11:15 Mojtaba Ghadiri, University of Leeds Particle breakage modelling 11:15 11:45 Jim Litster, University of Sheffield Wet granulation experimental and modelling 11:45 12:15 James Elliott, University of Cambridge Compaction modelling (and DEM solution on DEM modelling) 12:15 13:20 Lunch 13:20 13:50 Industrial Perspective – Kendall Pitt, GlaxoSmithKline The MCS – The Drive From Industry 13:50 14:30 Keynote #2 – Amrit Paudel, Research Centre for Pharmaceutical Engineering Stability by Design 14:30 14:50 Refreshment Break 14:50 15:20 Richard Storey, AstraZeneca Towards the Perfect Particle: What are the important design attributes? 15:20 16:00 Costas Pantelides, Process Systems Enterprise ADDoPT Vision: System-based Pharmaceutics 16:00 16:30 Summary and Close
Follow us
 
Upcoming Events
APS Board and Advisory Board Meeting
18 January 2017
APS Developability Workshop
22 - 23 March 2017
APS Industrial Insights 2017
20 - 21 April 2017
APS Board and Advisory Board Meeting
12 July 2017
APS 8th International PharmSci Conference 2017
5 - 7 September 2017
Job Vacancies
View all Vacancies
Advertise your job vacancies
Sponsored By
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.

 

The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365
Email: info@apsgb.org

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.